Integrated Immunological Engineering Platform for Scalable Production of iPSC ‐Derived Megakaryocytes
HLA · 2026
DOI: 10.1111/tan.70870 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2026. Verfasst von Rabea Dettmer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Megakaryocytes, Induced Pluripotent Stem Cells, Blood Platelets. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr, Stiftung des DRK-Blutspendienst NSTOB.
Abstract (Originalsprache)
Severe thrombocytopenia and impaired platelet function remain major clinical challenges in hematologic diseases, chemotherapy, bone marrow failure, surgery and obstetric haemorrhage. Conventional platelet transfusions are limited by donor dependency, short shelf life, storage constraints, and immune‐mediated platelet refractoriness caused primarily by HLA incompatibility. Here, we present a scalable, donor‐independent platform to generate universally compatible, low‐immunogenic megakaryocytes (MKs) from induced pluripotent stem cells (iPSCs). Human iPSCs were genetically engineered by shRNA‐mediated silencing of β2‐microglobulin (β2M) and/or class II transactivator (CIITA). Differentiation of HLA‐silenced iPSCs resulted in MKs with reduced HLA class I and II expression, capable to release functional platelets in vitro and sustain platelet production in humanised mice with physiological distribution. To enhance product safety, gamma irradiation effectively eliminated proliferative contaminants while preserving MK function. This platform integrates immune engineering with scalable iPSC‐based manufacturing and safety optimization, addressing key limitations of conventional donor‐derived platelet products. Together, these findings demonstrate that HLA‐silenced iPSC‐derived MKs represent a promising off‐the‐shelf source of functional platelets with reduced immunogenicity. By combining donor‐independent production, targeted immune engineering, and scalable manufacturing, this promising approach has the potential to improve transfusion support, overcome platelet refractoriness associated with HLA incompatibility, and expand access to readily available platelet therapies across diverse clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
- Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
- Biostabilization Laboratory-Lower Saxony Centre for Biomedical Engineering, Implant Research and Development, University of Veterinary Medicine Hannover, Hannover, Germany.
- Unit for Reproductive Medicine-Clinic for Horses, University of Veterinary Medicine Hannover, Hannover, Germany.
ORCID-Profile: Rabea Dettmer, Alice Rovai, Linus Schröder, Rainer Blasczyk
Förderung
- Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr
- Stiftung des DRK-Blutspendienst NSTOB
Zitieren
APA
Dettmer, R., Rovai, A., Schröder, L., Reinkens, T., Wolkers, W., Blasczyk, R., & Figueiredo, C. (2026). Integrated Immunological Engineering Platform for Scalable Production of iPSC ‐Derived Megakaryocytes. HLA. https://doi.org/10.1111/tan.70870
Vancouver
Dettmer R, Rovai A, Schröder L, Reinkens T, Wolkers W, Blasczyk R, et al. Integrated Immunological Engineering Platform for Scalable Production of iPSC ‐Derived Megakaryocytes. HLA. 2026. doi:10.1111/tan.70870
BibTeX
@article{Dettmer2026,
author = {Dettmer, Rabea and Rovai, Alice and Schröder, Linus and Reinkens, Thea and Wolkers, Willem and Blasczyk, Rainer and Figueiredo, Constanca},
title = {Integrated Immunological Engineering Platform for Scalable Production of iPSC ‐Derived Megakaryocytes},
journal = {HLA},
year = {2026},
doi = {10.1111/tan.70870}
}
EUVIMED